Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-VIEW: Aflibercept in Neovascular AMD
NCT01722045Phase 4Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2012
- Primary completion
- Sep 2015
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score From Baseline at 100 weeks. Started Nov 2012; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01722045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01722045.